Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Young TILs in Metastatic Melanoma
NCT00513604Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2007
- Primary completion
- Nov 2012
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of MDA-TIL in melanoma, sponsored by National Cancer Institute. Started Jun 2007; status: completed.
02
Drugs
MDA-TIL
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00513604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00513604.